Page last updated: 2024-08-25

rosiglitazone and Myocardial Infarction

rosiglitazone has been researched along with Myocardial Infarction in 163 studies

Research

Studies (163)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	92 (56.44)	29.6817
2010's	70 (42.94)	24.3611
2020's	1 (0.61)	2.80

Authors

Authors	Studies
Hansen, S; Rice, K	1
Kolesnik, E; Resl, M; Sourij, H; von Lewinski, D; Wallner, M	1
Liu, J; Wang, LN	3
Cole, AL; Dusetzina, SB; Hickson, RP	1
Huang, Q; Li, D; Li, T; Li, Z; Lu, Y; Pan, Z; Wu, H; Yang, T; Yang, W; Zhan, L; Zhang, G; Zhuang, Y	1
Abdullah, SM; Ayers, CR; de Lemos, JA; Gada, E; Gore, MO; Khera, A; McGuire, DK; Owens, AW; Rohatgi, A; See, R	1
Tucker, ME	1
Bach, RG; Brooks, MM; Donner, TW; Frye, RL; Garber, A; Genuth, S; Kelsey, SF; Kennedy, L; Lombardero, M; Monrad, ES; Pop-Busui, R	2
Mitka, M	3
Bigelow, R; Burns, S; Dickerson, S; Hafley, G; Home, PD; Komajda, M; Lopes, RD; Mahaffey, KW; McMurray, J; Newby, LK; Tourt-Uhlig, S; White, J	2
Hiatt, WR; Kaul, S; Smith, RJ	1
Azeloglu, EU; Badimon, JJ; Benard, L; Chen, Y; Giannarelli, C; Goldfarb, J; Gottesman, O; Hajjar, RJ; Iyengar, R; Nishimura, T; Zafar, MU; Zhao, S	1
A Wahab, I; Kalisch, LM; Pratt, NL; Roughead, EE	1
McCarthy, M	1
DiNicolantonio, JJ; Meier, P	1
Rawson, NS	1
Prasad, V	1
Barendregt, JJ; Doi, SA; Furuya-Kanamori, L; Stone, JC	1
Dangi-Garimella, S	1
Chen, Y; Han, H; Liu, B; Wang, J; Xu, F; Xue, M; Yuan, Q	1
Abraira, C; Bahn, G; Duckworth, W; Emanuele, N; Florez, H; Hayward, R; Marks, J; Moritz, T; Reaven, PD; Reda, D; Warren, S	1
Ahuja, V; Birge, JR; Budiman-Mak, E; Cooper, JM; Emanuele, N; Huang, ES; Sohn, MW; Syverson, C	1
Abdullah, SM; Ayers, CR; de Lemos, JA; Gore, MO; Grinsfelder, DB; Khera, A; McGuire, DK; Neeland, IJ; Pandey, A; Salahuddin, UI; See, R	1
Calingaert, B; Margulis, AV; Perez-Gutthann, S; Pladevall, M; Riera-Guardia, N; Varas-Lorenzo, C	1
Fu, H; Gaydos, BL; Heine, RJ; Hoogwerf, BJ; Manner, DH; Moscarelli, E	1
Rücker, G; Schumacher, M	1
Buse, JB	1
Abe, M; Ichimaru, S; Kaji, S; Takiguchi, Y; Tsuchiya, K; Wada, K	1
Diamond, GA; Kaul, S	2
Loke, YK; Singh, S	1
Mannucci, E; Marchionni, N; Monami, M	2
Carter, L; Odom, J; Williamson, B	1
Christopher, TA; Gao, E; Koch, W; Lau, WB; Liu, HR; Lopez, BL; Ma, XL; Qu, Y; Tao, L; Yue, TL	1
Levin, R; Setoguchi, S; Solomon, DH; Winkelmayer, WC	1
Kollar, C; Waksman, J	1
Divine, G; Habib, ZA; Havstad, SL; Krajenta, R; Lanfear, DE; Pladevall, M; Tang, J; Tzogias, L; Wells, K; Williams, LK	1
Di Bari, M; Gensini, GF; Gori, F; Lamanna, C; Mannucci, E; Marchionni, N; Monami, M	1
Bairey Merz, CN; Borer, JS; Borzak, SL; DeMets, DL; Hennekens, CH	1
Nesto, RW; Zarich, SW	1
Retnakaran, R; Zinman, B	1
Beck-Nielsen, H; Curtis, PS; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ	1
Dore, DD; Lapane, KL; Mor, V; Trivedi, AN	1
Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Schneeweiss, S; Wright, JM	1
Dong, YG; Ma, H; Ma, YD; Tang, AL; Wu, JG; Xiong, ZB; Zhang, XJ	1
Brath, H; Ludvik, B; Toplak, H; Wascher, T	1
Austin, PC; Gomes, T; Hux, JE; Juurlink, DN; Lipscombe, LL; Mamdani, MM	1
de Vries, CS; Russell-Jones, DL	1
Jazet, IM; Meinders, AE	1
Chan, L; Gao, E; Koch, WJ; Lau, WB; Ma, XL; Tao, L; Wang, Y; Yuan, Y; Zhang, H	1
Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR	1
Arnold Chan, K; Koro, C; Landon, J; McAfee, AT; Ziyadeh, N	1
Bolger, AF; Eckel, RH; Giugliano, RP; Herrington, D; Kaul, S	1
McCoy, CP; Montori, VM; Murad, MH; Wang, AT	1
Nissen, SE	2
Asghari, S; Carpentier, AC; Courteau, J; Vanasse, A	1
Moynihan, R	1
Eggertson, L	1
Wadman, M	2
Tanne, JH	2
Juurlink, DN	1
Ali, F; Graham, DJ; Kelman, JA; MaCurdy, TE; Ouellet-Hellstrom, R; Sholley, C; Worrall, C	1
Cai, T; Parast, L; Ryan, L	1
Ledford, H	2
Nissen, SE; Wolski, K	2
Bohn, RL; Chang, CL; Cziraky, MJ; Sarawate, CA; Wertz, DA; Willey, VJ	1
Masoudi, FA	1
Bloomgarden, Z; Handelsman, Y	1
Hamburg, M; Sharfstein, JM; Woodcock, J	1
Chen, Y; Chu, H; Huang, Y; Nie, L; Sun, W	1
Bigiarini, M; Mannucci, E; Monami, M; Rotella, CM	1
Claggett, B; Wei, LJ	1
Krentz, AJ	1
Kwok, CS; Loke, YK; Singh, S	1
Beck-Nielsen, H; Curtis, PS; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; MacDonald, MR; McMurray, JJ; Petrie, MC; Pocock, SJ	1
Berthet, S; Lapeyre-Mestre, M; Montastruc, JL; Olivier, P	1
Chattipakorn, N; Chattipakorn, S; Palee, S; Surinkeaw, S; Weerateerangkul, P	1
Li, J; Morrison, A; Tong, C; Yan, X	1
Li, YC; Lu, YC	1
Chang, YW; Chen, WL; Chou, CC; Kao, TW; Loh, CH; Wang, CC	1
Wang, X	1
Chen, B; Desai, P; Ding, Y; He, B; Moorthy, G; Qiu, J; Shin, JH; Sun, Y; Tang, J; Wang, H; Wild, DJ	1
Lane, PW	1
Biagi, C; Marchesini, G; Marra, A; Motola, D; Piccinni, C; Poluzzi, E; Raschi, E	1
Home, P	1
Atar, D; Serebruany, VL	1
Tannen, R; Wang, X; Weiner, MG; Xie, D; Yu, M	1
Chattipakorn, N; Chattipakorn, SC; Chinda, K; Palee, S; Weerateerangkul, P	1
Clarke, K; Cole, MA; Hulbert, K; Lygate, CA; Monfared, M; Neubauer, S	1
Görtz, A; Lander, T; Reblin, T; Seidel, D; Stein, D	1
Bao, W; Cui, J; Gu, JL; Jucker, BM; Ma, XL; Ohlstein, EH; Tao, L; Yue, TL	1
Cho, L; Lewis, BE; Leya, FS; Steen, LH	1
Ao, Z; Costell, M; Douglas, SA; Eybye, M; Gruver, S; Johns, DG; Macphee, CH; Olzinski, A; Smith, SA	1
Chen, J; Mehta, JL; Molavi, B	1
Geng, DF; Jin, DM; Wang, JF; Wu, W; Wu, YM	1
Furberg, CD; Psaty, BM	2
Beck-Nielsen, H; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ	1
Curfman, GD; Drazen, JM; Morrissey, S	1
Koro, C; Landon, J; McAfee, AT; Walker, AM; Ziyadeh, N	1
Couzin, J	1
Thomas, IR	1
Krall, RL	1
Farkouh, ME; Fuster, V	1
Hjelmesaeth, J	1
Lepor, NE; McCullough, PA	1
Psaty, B	2
Bossuyt, PM; de Vries, JH; Hoekstra, JB	1
McGuire, DK	1
Grant, PJ	1
Marx, N	1
Bax, L; Diamond, GA; Kaul, S	1
Lewis, JD; Strom, BL	1
Drzewoski, J; Grzeszczak, W	1
Bilous, RW	1
Bloomgarden, ZT	1
Bracken, MB	1
Susman, J	1
Jones, LS; Salmon, DA; Shuster, JJ	1
Hampton, T	1
Furberg, CD; Loke, YK; Singh, S	1
Atkin, SL; Cleland, JG	1
Gilbert, RE	1
Cornell, J; Localio, AR; Mulrow, CD	1
Comarow, A	1
Wolffenbuttel, BH	1
Florez, H; Meneghini, LF; Tamariz, L	1
Boyle, P	1
Koro, C; McAfee, AT; Walker, AM	1
Carpenter, J; Rücker, G; Schwarzer, G	1
Alter, DA; Gomes, T; Hux, JE; Juurlink, DN; Lévesque, LE; Lipscombe, LL	1
Vastag, B	1
Erdmann, E; Scherbaum, WA	1
Bégaud, B; Bernard, MH; Eschwège, E; Grimaldi, A; Oppert, JM; Pouchain, D; Slama, G	1
Schatz, DA; Shuster, JJ	1
Mikhail, N	1
Kapoor, JR	1
Dahabreh, IJ; Economopoulos, K	1
Koro, CE; Landon, J; Walker, AM	1
Achtari Jeanneret, L; Barras-Moret, AC; Carron, P; Deriaz-Chessex, S; Donzé, J; Fournier, Y; Gachoud, D; Moix, PA; Monti, M; Rossier, A; Wilson, P	1
Bao, W; Boyce, R; Bril, A; Buckingham, RE; Chen, J; Gu, JL; Hart, TK; Jiang, W; Lysko, PG; Narayanan, PK; Ohlstein, EH; Yue Tl, TL; Zimmerman, DM	1
Chatterjee, PK; Cuzzocrea, S; Hattori, Y; McDonald, MC; Mota-Filipe, H; Pisano, B; Thiemermann, C; Wayman, NS	1

Reviews

25 review(s) available for rosiglitazone and Myocardial Infarction

Article	Year
Exact inference for fixed effects meta-analysis of Statistics in medicine, 2023, 08-30, Volume: 42, Issue:19 Topics: Humans; Likelihood Functions; Myocardial Infarction; Rosiglitazone	2023
New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data. BioMed research international, 2017, Volume: 2017 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones	2017
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. The Cochrane database of systematic reviews, 2017, 12-02, Volume: 12 Topics: Cardiovascular Diseases; Carotid Artery Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Proteasome Endopeptidase Complex; Randomized Controlled Trials as Topic; Recurrence; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones; Ubiquitin	2017
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack. The Cochrane database of systematic reviews, 2014, Jan-08, Issue:1 Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones	2014
Review of the quality of observational studies of the association between rosiglitazone and acute myocardial infarction. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, 2014, Volume: 21, Issue:2 Topics: Humans; Myocardial Infarction; Observational Studies as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones; United States; Vasodilator Agents	2014
Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes? Pharmacoepidemiology and drug safety, 2015, Volume: 24, Issue:3 Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Mortality; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones	2015
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack. The Cochrane database of systematic reviews, 2015, Oct-29, Issue:10 Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones	2015
Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies. BMC cardiovascular disorders, 2016, Jan-15, Volume: 16 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Observational Studies as Topic; Pioglitazone; Risk Factors; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones	2016
Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications. Diabetes care, 2016, Volume: 39 Suppl 2 Topics: Cardiovascular Diseases; Diabetes Mellitus; Drug Discovery; Drug Evaluation, Preclinical; Drug Industry; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2016
Rosiglitazone and cardiovascular risk. Current atherosclerosis reports, 2008, Volume: 10, Issue:5 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Thiazolidinediones	2008
The safety of rosiglitazone in the treatment of type 2 diabetes. Expert opinion on drug safety, 2008, Volume: 7, Issue:5 Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones	2008
Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone. Diabetes research and clinical practice, 2008, Volume: 82, Issue:1 Topics: Aged; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides	2008
Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. International journal of cardiology, 2010, Aug-20, Volume: 143, Issue:2 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones	2010
Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ (Clinical research ed.), 2010, Mar-18, Volume: 340 Topics: Conflict of Interest; Cross-Sectional Studies; Diabetes Mellitus; Disclosure; Drug Industry; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones	2010
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Archives of internal medicine, 2010, Jul-26, Volume: 170, Issue:14 Topics: Biomarkers; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus; Europe; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Registries; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2010
Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: methods for the absolute risk difference and relative risk. Statistical methods in medical research, 2012, Volume: 21, Issue:6 Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; Models, Statistical; Myocardial Infarction; Outcome Assessment, Health Care; Pregnancy; Risk; Rosiglitazone; Thiazolidinediones	2012
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ (Clinical research ed.), 2011, Mar-17, Volume: 342 Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Prognosis; Publication Bias; Risk Factors; Rosiglitazone; Thiazolidinediones	2011
Assessment of cardiac safety for PPARγ agonists in rodent models of heart failure: a translational medicine perspective. Current molecular pharmacology, 2012, Volume: 5, Issue:2 Topics: Animals; Biomarkers; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression Profiling; Heart Failure; Hypoglycemic Agents; Kidney; Myocardial Infarction; PPAR gamma; Rosiglitazone; Thiazolidinediones; Translational Research, Biomedical	2012
Meta-analysis of incidence of rare events. Statistical methods in medical research, 2013, Volume: 22, Issue:2 Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Meta-Analysis as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rosiglitazone; Thiazolidinediones	2013
Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes. Diabetes technology & therapeutics, 2012, Volume: 14 Suppl 1 Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United Kingdom	2012
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England journal of medicine, 2007, Jun-14, Volume: 356, Issue:24 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Odds Ratio; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones	2007
The rosiglitazone meta-analysis. Reviews in cardiovascular medicine, 2007,Spring, Volume: 8, Issue:2 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA, 2007, Sep-12, Volume: 298, Issue:10 Topics: Cardiac Output, Low; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk; Rosiglitazone; Thiazolidinediones	2007
Why should we avoid the use of rosiglitazone? Southern medical journal, 2008, Volume: 101, Issue:3 Topics: Diabetes Mellitus; Double-Blind Method; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Odds Ratio; Proportional Hazards Models; Rosiglitazone; Thiazolidinediones	2008
Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clinical trials (London, England), 2008, Volume: 5, Issue:2 Topics: Cardiovascular Diseases; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones	2008

Trials

7 trial(s) available for rosiglitazone and Myocardial Infarction

Article	Year
Discordant effects of rosiglitazone on novel inflammatory biomarkers. American heart journal, 2013, Volume: 165, Issue:4 Topics: Aged; Atherosclerosis; Biomarkers; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Female; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Lymphotoxin beta Receptor; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Rosiglitazone; Thiazolidinediones	2013
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation, 2013, Aug-20, Volume: 128, Issue:8 Topics: Aged; Angioplasty; Comorbidity; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome	2013
Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:10 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Propensity Score; Proportional Hazards Models; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; United States; United States Department of Veterans Affairs	2015
Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus. Diabetes & vascular disease research, 2016, Volume: 13, Issue:2 Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones; Troponin	2016
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (London, England), 2009, Jun-20, Volume: 373, Issue:9681 Topics: Administration, Oral; Angina, Unstable; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Drug Utilization; Female; Fractures, Bone; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Neoplasms; Prospective Studies; Rosiglitazone; Sex Factors; Stroke; Sulfonylurea Compounds; Thiazolidinediones	2009
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes care, 2011, Volume: 34, Issue:6 Topics: Diabetes Mellitus, Type 2; Incidence; Myocardial Infarction; Prevalence; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2011
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. The New England journal of medicine, 2007, Jul-05, Volume: 357, Issue:1 Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Myocardial Infarction; Risk; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2007

Other Studies

131 other study(ies) available for rosiglitazone and Myocardial Infarction

Article	Year
Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. Journal of managed care & specialty pharmacy, 2019, Volume: 25, Issue:1 Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Labeling; Humans; Middle Aged; Myocardial Infarction; Pioglitazone; Retrospective Studies; Rosiglitazone; Young Adult	2019
Involvement of lncR-30245 in Myocardial Infarction-Induced Cardiac Fibrosis Through Peroxisome Proliferator-Activated Receptor-γ-Mediated Connective Tissue Growth Factor Signalling Pathway. The Canadian journal of cardiology, 2019, Volume: 35, Issue:4 Topics: Animals; Benzamides; Cell Proliferation; Collagen; Connective Tissue Growth Factor; Fibroblasts; Fibrosis; Heart Diseases; Mice, Inbred C57BL; Models, Animal; Myocardial Infarction; PPAR gamma; Pyridines; RNA, Long Noncoding; Rosiglitazone; Stroke Volume; Transforming Growth Factor beta1; Up-Regulation	2019
FDA panel advises easing restrictions on rosiglitazone. BMJ (Clinical research ed.), 2013, Jun-10, Volume: 346 Topics: Diabetes Mellitus; Drug and Narcotic Control; Humans; Hypoglycemic Agents; Myocardial Infarction; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2013
Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety. JAMA, 2013, Jul-17, Volume: 310, Issue:3 Topics: Advisory Committees; Decision Making; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2013
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American heart journal, 2013, Volume: 166, Issue:2 Topics: Follow-Up Studies; Humans; Hypoglycemic Agents; Mortality; Myocardial Infarction; Randomized Controlled Trials as Topic; Research Design; Rosiglitazone; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration	2013
Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American heart journal, 2013, Volume: 166, Issue:2 Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Mortality; Myocardial Infarction; Randomized Controlled Trials as Topic; Research Design; Rosiglitazone; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration	2013
The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Europe; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration	2013
Systems pharmacology of adverse event mitigation by drug combinations. Science translational medicine, 2013, Oct-09, Volume: 5, Issue:206 Topics: Adverse Drug Reaction Reporting Systems; Animals; Blood Coagulation; Confounding Factors, Epidemiologic; Databases as Topic; Diabetes Mellitus, Experimental; Drug Combinations; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Exenatide; Heart Function Tests; Humans; Mice; Myocardial Infarction; Peptides; Plasminogen Activator Inhibitor 1; Rosiglitazone; Systems Biology; Thiazolidinediones; Thrombelastography; Ultrasonography; United States; United States Food and Drug Administration; Venoms	2013
Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. Drug safety, 2014, Volume: 37, Issue:1 Topics: Adverse Drug Reaction Reporting Systems; Australia; Bayes Theorem; Cyclooxygenase 2 Inhibitors; Databases, Factual; Heart Failure; Humans; Hypoglycemic Agents; Lactones; Myocardial Infarction; Neural Networks, Computer; Product Surveillance, Postmarketing; Rosiglitazone; Sulfones; Thiazolidinediones; Time Factors	2014
US regulators relax restrictions on rosiglitazone. BMJ (Clinical research ed.), 2013, Nov-28, Volume: 347 Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2013
Is rosiglitazone as safe as BARI 2D and the reanalysis of RECORD imply? Cardiology, 2014, Volume: 127, Issue:3 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Myocardial Infarction; Randomized Controlled Trials as Topic; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones	2014
FDA eases restrictions on the glucose-lowering drug rosiglitazone. JAMA, 2013, Dec-25, Volume: 310, Issue:24 Topics: Death, Sudden, Cardiac; Diabetes Mellitus; Humans; Hypoglycemic Agents; Myocardial Infarction; Practice Patterns, Physicians'; Risk; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2013
In brief: rosiglitazone (Avandia) unbound. The Medical letter on drugs and therapeutics, 2014, Feb-03, Volume: 56, Issue:1435 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Assessment; Risk Factors; Rosiglitazone; Stroke; Thiazolidinediones	2014
Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial". Circulation, 2014, Apr-22, Volume: 129, Issue:16 Topics: Angioplasty; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2014
Rosiglitazone, medical reversal, and back to basics for diabetes. American family physician, 2014, Sep-15, Volume: 90, Issue:6 Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Risk Assessment; Rosiglitazone; Thiazolidinediones	2014
The Yin and the Yang of CV risks in patients with diabetes. The American journal of managed care, 2014, Volume: 20, Issue:8 Spec No. Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration	2014
Acute Hepatic Insulin Resistance Contributes to Hyperglycemia in Rats Following Myocardial Infarction. Molecular medicine (Cambridge, Mass.), 2015, Feb-23, Volume: 21 Topics: Animals; Blood Glucose; Gluconeogenesis; Hyperglycemia; Insulin; Insulin Resistance; Liver; Male; Muscle, Skeletal; Myocardial Infarction; Rats; Receptor, Insulin; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tumor Necrosis Factor-alpha	2015
Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs. Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:12 Topics: Aged; Biomarkers; Blood Glucose; Delivery of Health Care, Integrated; Diabetes Mellitus; Drug Labeling; Drug Utilization Review; Female; Healthcare Disparities; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Practice Patterns, Physicians'; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; United States Food and Drug Administration	2015
Simpson's paradox visualized: the example of the rosiglitazone meta-analysis. BMC medical research methodology, 2008, May-30, Volume: 8 Topics: Child; Data Interpretation, Statistical; Electric Power Supplies; Humans; Leukemia; Meta-Analysis as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Rosiglitazone; Sample Size; Statistics as Topic; Thiazolidinediones	2008
Are prescribing patterns of antidiabetic medications influenced by fears of litigation? Nature clinical practice. Endocrinology & metabolism, 2008, Volume: 4, Issue:8 Topics: Drug Prescriptions; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones	2008
Different effect of acute treatment with rosiglitazone on rat myocardial ischemia/reperfusion injury by administration method. European journal of pharmacology, 2008, Jul-28, Volume: 589, Issue:1-3 Topics: Acetylcysteine; Animals; Antioxidants; Computer Simulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; I-kappa B Proteins; Infusions, Intravenous; Injections, Intravenous; Male; Models, Biological; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; NF-kappa B; Peroxidase; Phosphorylation; PPAR gamma; Protective Agents; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2008
Rosiglitazone and pioglitazone in the treatment of diabetes mellitus. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Oct-01, Volume: 65, Issue:19 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; PPAR gamma; Practice Guidelines as Topic; Rosiglitazone; Thiazolidinediones	2008
Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation--a novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovascular research, 2009, Feb-01, Volume: 81, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Caspase 3; Gene Expression Regulation, Enzymologic; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Lipoproteins, LDL; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Peroxidase; PPAR gamma; Rabbits; Rosiglitazone; Thiazolidinediones	2009
Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Archives of internal medicine, 2008, Nov-24, Volume: 168, Issue:21 Topics: Aged; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome	2008
Comments on 'Rebuttal to Carpenter et al.' Comments on 'Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death' by J. J. Shuster, L. S. Jones and D. A. Salmon, Statistics in Medicin Statistics in medicine, 2009, Feb-01, Volume: 28, Issue:3 Topics: Death; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2009
Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:6 Topics: Acute Disease; Cardiovascular Diseases; Cohort Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome	2009
Doing more good than harm: need for a cease fire. The American journal of medicine, 2009, Volume: 122, Issue:4 Topics: Humans; Mass Media; Meta-Analysis as Topic; Myocardial Infarction; Publications; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones; Vasodilator Agents	2009
Editorial: What have we lost in the wake of the rosiglitazone controversy? Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2009, Volume: 15, Issue:3 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Withholding Treatment	2009
Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet (London, England), 2009, Jun-20, Volume: 373, Issue:9681 Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones	2009
Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction. Pharmacotherapy, 2009, Volume: 29, Issue:7 Topics: Aged; Aged, 80 and over; Case-Control Studies; Databases, Factual; Female; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones; Time Factors; United States	2009
Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PloS one, 2009, Jun-27, Volume: 4, Issue:6 Topics: Aged; Case-Control Studies; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Medical Records Systems, Computerized; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Regression Analysis; Risk; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2009
Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase/Akt-dependent pathway. Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:2 Topics: Androstadienes; Animals; Blood Glucose; Glycogen Synthase Kinase 3; Male; Mice; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphatidylinositol 3-Kinases; PPAR gamma; Proto-Oncogene Proteins c-akt; Rats; Rosiglitazone; Thiazolidinediones; Ventricular Fibrillation; Wortmannin	2010
[The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus]. Wiener klinische Wochenschrift, 2009, Volume: 121, Issue:13-14 Topics: Austria; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin Glargine; Insulin, Long-Acting; Myocardial Infarction; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2009
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ (Clinical research ed.), 2009, Aug-18, Volume: 339 Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2009
Rosiglitazone or pioglitazone in type 2 diabetes? BMJ (Clinical research ed.), 2009, Aug-18, Volume: 339 Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2009
[Rosiglitazone: no increase in cardiovascular mortality]. Nederlands tijdschrift voor geneeskunde, 2009, Volume: 153 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2009
Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circulation research, 2010, Feb-05, Volume: 106, Issue:2 Topics: Adipocytes; Adiponectin; Animals; Apoptosis; Capillaries; Cardiotonic Agents; Enzyme-Linked Immunosorbent Assay; Female; Heart Function Tests; Humans; Hypoglycemic Agents; In Situ Nick-End Labeling; Male; Mice; Mice, Knockout; Myocardial Infarction; Platelet Endothelial Cell Adhesion Molecule-1; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Survival Analysis; Thiazolidinediones; Treatment Outcome; Tumor Necrosis Factor-alpha	2010
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ (Clinical research ed.), 2009, Dec-03, Volume: 339 Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2009
The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clinical therapeutics, 2009, Volume: 31, Issue:11 Topics: Adult; Aged; Cohort Studies; Coronary Disease; Death, Sudden; Female; Follow-Up Studies; Heart Rate; Humans; Hypoglycemic Agents; Insurance Claim Review; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Rosiglitazone; Survival Analysis; Thiazolidinediones; Treatment Outcome; United States	2009
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation, 2010, Apr-27, Volume: 121, Issue:16 Topics: Advisory Committees; American Heart Association; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Prevalence; Risk Factors; Rosiglitazone; Thiazolidinediones; United States	2010
Setting the RECORD Straight. JAMA, 2010, Mar-24, Volume: 303, Issue:12 Topics: Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Drug Industry; Editorial Policies; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Peer Review, Research; Randomized Controlled Trials as Topic; Research Design; Rosiglitazone; Thiazolidinediones	2010
Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients. Diabetes & vascular disease research, 2009, Volume: 6, Issue:2 Topics: Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus; Drug Prescriptions; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Logistic Models; Myocardial Infarction; Odds Ratio; Quebec; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome	2009
Rosiglitazone, marketing, and medical science. BMJ (Clinical research ed.), 2010, Apr-07, Volume: 340 Topics: Clinical Trials as Topic; Conflict of Interest; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Interprofessional Relations; Marketing of Health Services; Meta-Analysis as Topic; Myocardial Infarction; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration	2010
Researcher urges Health Canada to suspend "unethical" diabetes drug trial. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2010, Jul-13, Volume: 182, Issue:10 Topics: Canada; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones	2010
Avandia outcome may signal change in epidemiologists' sway. Nature medicine, 2010, Volume: 16, Issue:6 Topics: Clinical Trials as Topic; Drug Approval; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2010
GlaxoSmithKline denies it has settled thousands of lawsuits over rosiglitazone (Avandia). BMJ (Clinical research ed.), 2010, Jun-07, Volume: 340 Topics: Compensation and Redress; Drug Industry; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Stroke; Thiazolidinediones	2010
Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues. JAMA, 2010, Jun-16, Volume: 303, Issue:23 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Risk; Rosiglitazone; Thiazolidinediones; Time Factors; United States; United States Food and Drug Administration	2010
Diabetes drug safety update: Avandia and your heart. The Johns Hopkins medical letter health after 50, 2010, Volume: 22, Issue:4 Topics: Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2010
Rosiglitazone and the case for safety over certainty. JAMA, 2010, Jul-28, Volume: 304, Issue:4 Topics: Decision Making; Diabetes Mellitus, Type 2; Heart Failure; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones	2010
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA, 2010, Jul-28, Volume: 304, Issue:4 Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Medicare Part D; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Stroke; Thiazolidinediones; United States	2010
Meta-analysis for rare events. Statistics in medicine, 2010, Sep-10, Volume: 29, Issue:20 Topics: Biostatistics; Cardiovascular Diseases; Humans; Hypoglycemic Agents; Likelihood Functions; Meta-Analysis as Topic; Models, Statistical; Myocardial Infarction; Poisson Distribution; Risk; Rosiglitazone; Thiazolidinediones	2010
Diabetes drugs offered fresh start. Nature, 2010, Jul-22, Volume: 466, Issue:7305 Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Humans; Mice; Myocardial Infarction; PPAR gamma; Risk; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2010
Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:5 Topics: Female; Heart Failure; Humans; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Pioglitazone; Population Groups; Retrospective Studies; Risk Assessment; Rosiglitazone; Survival Analysis; Thiazolidinediones; United States	2010
Improving drug safety surveillance: lessons from rosiglitazone. Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:5 Topics: Clinical Trials as Topic; Heart Failure; Humans; Managed Care Programs; Myocardial Infarction; Quality Assurance, Health Care; Risk; Rosiglitazone; Survival Analysis; Thiazolidinediones; United States	2010
The Avandia debate: an unhappy conclusion. Journal of diabetes, 2010, Volume: 2, Issue:4 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Europe; Government Agencies; Humans; Hypoglycemic Agents; Insulin; Myocardial Infarction; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2010
Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug and Narcotic Control; Humans; Myocardial Infarction; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2010
Inaccuracy in meta-analysis on rosiglitazone and myocardial infarction. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2011, Volume: 21, Issue:2 Topics: Humans; Meta-Analysis as Topic; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2011
Analytical issues regarding rosiglitazone meta-analysis. Archives of internal medicine, 2011, Jan-24, Volume: 171, Issue:2 Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2011
Rosiglitazone: trials, tribulations and termination. Drugs, 2011, Jan-22, Volume: 71, Issue:2 Topics: Controlled Clinical Trials as Topic; Drug Approval; Europe; History, 21st Century; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States	2011
Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. BMC clinical pharmacology, 2011, May-24, Volume: 11 Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Databases, Factual; Diabetes Mellitus, Type 2; Edema; Female; France; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones	2011
Effect of rosiglitazone on cardiac electrophysiology, infarct size and mitochondrial function in ischaemia and reperfusion of swine and rat heart. Experimental physiology, 2011, Volume: 96, Issue:8 Topics: Animals; Cardiac Electrophysiology; Coronary Circulation; Coronary Vessels; Electric Countershock; Female; Heart; Male; Membrane Potential, Mitochondrial; Mitochondria, Heart; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Reactive Oxygen Species; Rosiglitazone; Swine; Thiazolidinediones; Ventricular Fibrillation	2011
Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice. American journal of physiology. Heart and circulatory physiology, 2011, Volume: 301, Issue:3 Topics: AMP-Activated Protein Kinases; Anilides; Animals; Cardiotonic Agents; Disease Models, Animal; Drug Administration Schedule; Enzyme Activation; Injections, Intravenous; JNK Mitogen-Activated Protein Kinases; Male; Mice; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Phosphorylation; PPAR gamma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Rosiglitazone; Signal Transduction; Thiazolidinediones; Time Factors; Ventricular Function, Left; Ventricular Pressure	2011
How doctors practice evidence-based medicine. Journal of evaluation in clinical practice, 2013, Volume: 19, Issue:1 Topics: Adult; Age Factors; Diabetes Mellitus; Evidence-Based Medicine; Female; Health Knowledge, Attitudes, Practice; Humans; Hypoglycemic Agents; Male; Medicine; Middle Aged; Myocardial Infarction; Practice Patterns, Physicians'; Residence Characteristics; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2013
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Clinical therapeutics, 2011, Volume: 33, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Taiwan; Thiazolidinediones; Time Factors; Treatment Outcome	2011
Mining relational paths in integrated biomedical data. PloS one, 2011, Volume: 6, Issue:12 Topics: Algorithms; Computers; Data Collection; Data Mining; Databases, Factual; Humans; Hypoglycemic Agents; Ibuprofen; Medical Informatics; Models, Statistical; Myocardial Infarction; Parkinson Disease; Pioglitazone; Rosiglitazone; Software; Thiazolidinediones	2011
Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug safety, 2012, Apr-01, Volume: 35, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Bone and Bones; Cardiovascular System; Clinical Trials as Topic; Databases, Factual; Eye; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Macular Edema; Male; Meta-Analysis as Topic; Myocardial Infarction; Odds Ratio; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2012
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO? Thrombosis and haemostasis, 2012, Volume: 108, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor	2012
A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. Pharmacoepidemiology and drug safety, 2013, Volume: 22, Issue:1 Topics: Adult; Aged; Cohort Studies; Comparative Effectiveness Research; Databases, Factual; Diabetes Mellitus, Type 2; Electronic Health Records; Feasibility Studies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Randomized Controlled Trials as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2013
Mechanisms responsible for beneficial and adverse effects of rosiglitazone in a rat model of acute cardiac ischaemia-reperfusion. Experimental physiology, 2013, Volume: 98, Issue:5 Topics: Animals; Arrhythmias, Cardiac; Calcium; Caspase 3; Caspase 8; Heart; Male; Mitochondria, Heart; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocytes, Cardiac; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones	2013
The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovascular research, 2003, Jun-01, Volume: 58, Issue:3 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cardiotonic Agents; Drug Therapy, Combination; Echocardiography; Heart Failure; Male; Myocardial Infarction; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Treatment Failure; Ventricular Remodeling	2003
[Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough]. MMW Fortschritte der Medizin, 2003, May-08, Volume: 145, Issue:19 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes, 2005, Volume: 54, Issue:2 Topics: Administration, Oral; Animals; Blood Glucose; Coronary Vessels; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Heart; Hypoglycemic Agents; Insulin Resistance; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides	2005
Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention. Cardiology, 2005, Volume: 104, Issue:2 Topics: Aged; Angioplasty, Balloon, Coronary; Cause of Death; Coronary Circulation; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Rosiglitazone; Stents; Survival Rate; Thiazolidinediones	2005
Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the zucker diabetic fatty rat. The Journal of pharmacology and experimental therapeutics, 2005, Volume: 315, Issue:3 Topics: Adiponectin; Animals; Blood Glucose; Blood Pressure; Cell Adhesion; Fatty Acids, Nonesterified; Hypoglycemic Agents; Immunohistochemistry; Insulin; Leukocytes; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Vascular Cell Adhesion Molecule-1	2005
Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. American journal of physiology. Heart and circulatory physiology, 2006, Volume: 291, Issue:2 Topics: Angiotensin I; Angiotensin II; Animals; Blood Glucose; Cardiotonic Agents; Enzyme Inhibitors; Hemodynamics; Hypoglycemic Agents; Immunohistochemistry; Ligands; Male; Mitogen-Activated Protein Kinase 1; Myocardial Infarction; Myocardium; PPAR gamma; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones	2006
Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction. International journal of cardiology, 2006, Oct-26, Volume: 113, Issue:1 Topics: Angiotensin II; Animals; Blood Glucose; Body Weight; Collagen; Insulin; Ligands; Liver; Lung; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Organ Size; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Ventricular Remodeling	2006
Rosiglitazone and cardiovascular risk. The New England journal of medicine, 2007, Jun-14, Volume: 356, Issue:24 Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2007
Study indicates diabetes drug linked to cardiovascular death. BMJ (Clinical research ed.), 2007, May-26, Volume: 334, Issue:7603 Topics: Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2007
Weighing up the evidence. Nature, 2007, May-31, Volume: 447, Issue:7144 Topics: Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus; Humans; Meta-Analysis as Topic; Myocardial Infarction; Patients; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone: seeking a balanced perspective. Lancet (London, England), 2007, Jun-02, Volume: 369, Issue:9576 Topics: Adult; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; Myocardial Infarction; Periodicals as Topic; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone--continued uncertainty about safety. The New England journal of medicine, 2007, Jul-05, Volume: 357, Issue:1 Topics: Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2007
The record on rosiglitazone and the risk of myocardial infarction. The New England journal of medicine, 2007, Jul-05, Volume: 357, Issue:1 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Drug Labeling; Hospitalization; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Research Design; Rosiglitazone; Thiazolidinediones; United States	2007
Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7 Topics: Adolescent; Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; United States	2007
Drug safety. Heart attack risk overshadows a popular diabetes therapy. Science (New York, N.Y.), 2007, Jun-15, Volume: 316, Issue:5831 Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus; Drug Industry; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Risk; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides	2007
Glycaemic control is a myth. BMJ (Clinical research ed.), 2007, Jun-16, Volume: 334, Issue:7606 Topics: Drug Approval; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2007
Cardiovascular safety of rosiglitazone. Lancet (London, England), 2007, Jun-16, Volume: 369, Issue:9578 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2007
Faster publication isn't always better. Nature clinical practice. Cardiovascular medicine, 2007, Volume: 4, Issue:7 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Peer Review, Research; Publishing; Randomized Controlled Trials as Topic; Research Design; Rosiglitazone; Thiazolidinediones; Time Factors	2007
[Increased risk of myocardial infarction following rosiglitazone?]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2007, Jun-28, Volume: 127, Issue:13 Topics: Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Straight talk from... Bruce Psaty. Interviewed by Emma Marris. Nature medicine, 2007, Volume: 13, Issue:7 Topics: Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Myocardial Infarction; Risk Assessment; Rosiglitazone; Thiazolidinediones; Time Factors; United States; United States Food and Drug Administration	2007
Heart-stopping news. The diabetes drug Avandia is under fire: what you should know. Interview by Avery Comarow. U.S. news & world report, 2007, Jun-04, Volume: 142, Issue:20 Topics: Blood Glucose; Diabetes Mellitus; Humans; Hypoglycemic Agents; Myocardial Infarction; Product Surveillance, Postmarketing; Risk Assessment; Rosiglitazone; Thiazolidinediones	2007
[Doubts as to the cardiovascular safety of rosiglitazone]. Nederlands tijdschrift voor geneeskunde, 2007, Jun-30, Volume: 151, Issue:26 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Safety; Thiazolidinediones	2007
Thiazolidinediones and cardiovascular disease. The Medical letter on drugs and therapeutics, 2007, Jul-16, Volume: 49, Issue:1265 Topics: Animals; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone and cardiovascular disease: an epidemiologist's perspective. Diabetes & vascular disease research, 2007, Volume: 4, Issue:2 Topics: Biomarkers; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Research Design; Risk Assessment; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2007
Rosiglitazone and cardiovascular disease: a diabetologist's perspective. Diabetes & vascular disease research, 2007, Volume: 4, Issue:2 Topics: Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Risk Assessment; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone and cardiovascular disease: a cardiologist's perspective. Diabetes & vascular disease research, 2007, Volume: 4, Issue:2 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Research Design; Risk Assessment; Rosiglitazone; Thiazolidinediones	2007
Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Annals of internal medicine, 2007, Oct-16, Volume: 147, Issue:8 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; PPAR gamma; Research Design; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
In clarification. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:10 Topics: Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
[Rosiglitazone--under fire]. Kardiologia polska, 2007, Volume: 65, Issue:7 Topics: Clinical Trials as Topic; Death; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2007
Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart. Harvard heart letter : from Harvard Medical School, 2007, Volume: 17, Issue:12 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis? Diabetic medicine : a journal of the British Diabetic Association, 2007, Volume: 24, Issue:9 Topics: Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Male; Metformin; Myocardial Infarction; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2007
The Avandia debate. Diabetes care, 2007, Volume: 30, Issue:9 Topics: Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone and cardiovascular risk. The New England journal of medicine, 2007, Aug-30, Volume: 357, Issue:9 Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Odds Ratio; Risk; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone: failure of oversight or demons imagined? The Journal of family practice, 2007, Volume: 56, Issue:9 Topics: Clinical Trials as Topic; Counseling; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Myocardial Infarction; Physician-Patient Relations; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2007
Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death. Statistics in medicine, 2007, Oct-30, Volume: 26, Issue:24 Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Logistic Models; Meta-Analysis as Topic; Models, Statistical; Myocardial Infarction; Odds Ratio; Proportional Hazards Models; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone and cardiovascular risk. The New England journal of medicine, 2007, Aug-30, Volume: 357, Issue:9 Topics: Bayes Theorem; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Odds Ratio; Risk; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone and cardiovascular risk. The New England journal of medicine, 2007, Aug-30, Volume: 357, Issue:9 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Risk; Rosiglitazone; Thiazolidinediones	2007
MI risks linked to rosiglitazone. JAMA, 2007, Sep-12, Volume: 298, Issue:10 Topics: Humans; Hypoglycemic Agents; Myocardial Infarction; Risk; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2007
Perspective: effect of rosiglitazone on cardiovascular outcomes. Current cardiology reports, 2007, Volume: 9, Issue:5 Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Myocardial Infarction; Odds Ratio; PPAR gamma; Risk Assessment; Rosiglitazone; Thiazolidinediones	2007
Ensuring drug safety: lessons from the thiazolidinediones. Lancet (London, England), 2007, Sep-29, Volume: 370, Issue:9593 Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hyperglycemia; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2007
Thiazolidinediones, deadly sins, surrogates, and elephants. Lancet (London, England), 2007, Sep-29, Volume: 370, Issue:9593 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Risk; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone: opening Pandora's black box? Clinical journal of the American Society of Nephrology : CJASN, 2007, Volume: 2, Issue:6 Topics: Diabetic Nephropathies; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone: a thunderstorm from scarce and fragile data. Annals of internal medicine, 2007, Oct-16, Volume: 147, Issue:8 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Research Design; Rosiglitazone; Thiazolidinediones	2007
Avandia in perspective. U.S. news & world report, 2007, Oct-01, Volume: 143, Issue:11 Topics: Blood Glucose; Diabetes Mellitus; Exercise; Health Behavior; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Obesity; Risk-Taking; Rosiglitazone; Thiazolidinediones; United States	2007
Health official speaks out about row over drug critic. Nature, 2007, Oct-25, Volume: 449, Issue:7165 Topics: Diabetes Mellitus; Drug Industry; History, 20th Century; History, 21st Century; Humans; Meta-Analysis as Topic; Myocardial Infarction; Research Personnel; Rosiglitazone; Thiazolidinediones	2007
[Doubts as to the cardiovascular safety of rosiglitazone]. Nederlands tijdschrift voor geneeskunde, 2007, Oct-06, Volume: 151, Issue:40 Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Safety; Thiazolidinediones; Time Factors	2007
The Avandia debacle: methodology and practical importance of the findings. Southern medical journal, 2007, Volume: 100, Issue:11 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones	2007
Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007. Southern medical journal, 2007, Volume: 100, Issue:11 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones	2007
Studies of diabetes, thiazolidinediones, and coronary heart disease. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:12 Topics: Coronary Disease; Diabetes Mellitus, Type 2; Hospitalization; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Comments on 'Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death'. Statistics in medicine, 2008, Aug-30, Volume: 27, Issue:19 Topics: Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Models, Statistical; Myocardial Infarction; Proportional Hazards Models; Rosiglitazone; Thiazolidinediones	2008
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA, 2007, Dec-12, Volume: 298, Issue:22 Topics: Aged; Aged, 80 and over; Cause of Death; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Thiazolidinediones	2007
Reviewer leaked Avandia study to drug firm. Nature, 2008, Jan-31, Volume: 451, Issue:7178 Topics: Diabetes Mellitus; Drug Industry; Ethics, Professional; Humans; Meta-Analysis as Topic; Myocardial Infarction; Peer Review, Research; Rosiglitazone; Thiazolidinediones; Truth Disclosure	2008
[Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect]. MMW Fortschritte der Medizin, 2007, Dec-06, Volume: 149, Issue:49-50 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Pioglitazone; Publishing; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
[One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study]. Annales d'endocrinologie, 2008, Volume: 69, Issue:1 Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Follow-Up Studies; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors	2008
The rosigliazone meta-analysis: lessons for the future. Diabetes care, 2008, Volume: 31, Issue:3 Topics: Death; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Myocardial Ischemia; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2008
Controversy over the cardiovascular effects of thiazolidinediones. The American journal of medicine, 2008, Volume: 121, Issue:4 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hyperglycemia; Insulin Resistance; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Survival Rate; Thiazolidinediones	2008
Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:8 Topics: Cohort Studies; Coronary Disease; Databases, Factual; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Outcome Assessment, Health Care; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2008
[Highlights 2007 in hospital-based internal medicine: the point of view from the chief residents]. Revue medicale suisse, 2008, Jan-30, Volume: 4, Issue:142 Topics: Accidental Falls; Aged; Albuterol; Anemia; Anticoagulants; Antidiuretic Hormone Receptor Antagonists; Atrial Fibrillation; Attitude of Health Personnel; Benzazepines; Bronchitis, Chronic; Bronchodilator Agents; Cardiac Pacing, Artificial; Diabetes Mellitus; Endocarditis, Bacterial; Erythropoietin; Heart Failure; Heparin; Humans; Internal Medicine; Interprofessional Relations; Medical Staff, Hospital; Myocardial Infarction; Recombinant Proteins; Risk Management; Rosiglitazone; Salmeterol Xinafoate; Thiazolidinediones; Thromboembolism; Tolvaptan; Vasodilator Agents; Ventricular Dysfunction, Left; Workload	2008
In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation, 2001, Nov-20, Volume: 104, Issue:21 Topics: Animals; CD18 Antigens; Cell Adhesion Molecules; Chemokine CCL2; Diabetes Complications; Hypoglycemic Agents; Macrophage-1 Antigen; Macrophages; Male; Monocytes; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion Injury; Neutrophil Infiltration; Neutrophils; Rats; Rats, Inbred Lew; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2001
[Infarct prevention for diabetics. To lower blood sugar is not enough]. MMW Fortschritte der Medizin, 2001, Nov-15, Volume: 143, Issue:46 Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents	2001
[Type 2 diabetes. How can the infarction risk be reduced?]. MMW Fortschritte der Medizin, 2002, Feb-28, Volume: 144, Issue:9 Topics: Acarbose; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Vasodilator Agents	2002
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2002, Volume: 16, Issue:9 Topics: Adult; Animals; Cardiotonic Agents; Cell Adhesion Molecules; Cell Line; Cells, Cultured; Chemokine CCL2; Clofibrate; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Ligands; Male; Membrane Proteins; Myocardial Infarction; Myocardial Reperfusion Injury; Pioglitazone; Prostaglandin D2; Prostaglandins A; Protein Isoforms; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2002